- VIGL Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Vigil Neuroscience (VIGL) 8-K23 Jan 25Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s DiseaseFinancial data
Company Profile